Bragar Eagel & Squire, P.C. Is Investigating Phathom, TuSimple, Mercury Systems, and Cassava and Encourages Investors to Contact the Firm
August 10, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals,...
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
August 06, 2022 13:16 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Bragar Eagel & Squire, P.C. Is Investigating MINISO, Digital World, Verano, and Phathom and Encourages Investors to Contact the Firm
August 05, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against MINISO Group Holding...
Phathom Pharmaceuticals Reports First Quarter 2020 Results
May 12, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates
March 19, 2020 08:30 ET
|
Phathom Pharmaceuticals
Successfully Finished 2019 with Initiation of Two Pivotal Phase 3 Trials for Vonoprazan in Erosive Esophagitis (PHALCON-EE) and H. pylori Infection (PHALCON-HP) and Completion of $209M Initial Public...
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
February 25, 2020 16:35 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...